Get the Stockscreener App
15.20
3.61%
0.53
After Hours:
15.20
Pulse Biosciences Inc stock is traded at $15.20, with a volume of 156.18K.
It is up +3.61% in the last 24 hours and up +14.54% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$14.67
Open:
$14.67
24h Volume:
156.18K
Relative Volume:
0.90
Market Cap:
$1.03B
Revenue:
$-9,000
Net Income/Loss:
$-68.03M
P/E Ratio:
-14.48
EPS:
-1.05
Net Cash Flow:
$-44.76M
1W Performance:
+10.71%
1M Performance:
+14.54%
6M Performance:
-3.86%
1Y Performance:
-18.06%
1-Day Range:
$14.64
$15.45
1-Week Range:
$13.17
$15.45
52-Week Range:
$12.56
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
15.20 | 994.15M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
592.27 | 210.16B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.71 | 58.51B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.02 | 40.19B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
248.21 | 36.37B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
40.43 | 31.30B | 27.43B | 1.27B | 1.01B | 1.5829 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Bluefield Daily Telegraph
(PLSE) Volatility Zones as Tactical Triggers - Stock Traders Daily
What analysts say about Pulse Biosciences Inc 6L8 stockEarnings Growth Projections & Test Our Stock Screener — Free Forever - earlytimes.in
Chipmakers Recap: How Pulse Biosciences Inc 6L8 stock responds to bond market - moha.gov.vn
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Total debt per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Positron (OTCMKTS:POSC) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Comparison - Defense World
What drives Pulse Biosciences Inc 6L8 stock priceHigh Dividend Yield Stocks & High Profit Market Growth - earlytimes.in
MSN Money - MSN
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Sahm
Pulse Biosciences Updates Investors on Product Advancements - MSN
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Can Pulse Biosciences Inc. stock beat market expectations this quarterEarnings Recap Report & Growth Focused Stock Reports - Улправда
Forecast Cut: Will Pulse Biosciences Inc. stock outperform tech sector in 2025July 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
What technical signals suggest for Pulse Biosciences Inc. stockSell Signal & AI Driven Price Forecasts - Улправда
How buybacks impact Pulse Biosciences Inc. stock valueEarnings Growth Summary & Long-Term Capital Growth Strategies - Улправда
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Market Pulse: How Aura Biosciences Inc. stock performs in high volatility marketsWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Aug Fed Impact: Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - Улправда
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial - sharewise.com
How Pulse Biosciences Inc. stock responds to policy changesMarket Risk Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Can Pulse Biosciences Inc. stock resist market sell offs2025 Support & Resistance & Community Verified Trade Signals - DonanımHaber
FDA approves Pulse Biosciences’ atrial fibrillation trial By Investing.com - Investing.com Australia
How Pulse Biosciences Inc. stock benefits from tech adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - DonanımHaber
Short Covering: Can Pulse Biosciences Inc. stock beat market expectations this quarter2025 Top Decliners & Long-Term Growth Plans - Улправда
Pulse Biosciences wins FDA approval to begin PFA catheter study - MedTech Dive
Can Pulse Biosciences Inc. (6L8) stock deliver double digit returns2025 Year in Review & Smart Investment Allocation Insights - ulpravda.ru
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial - TipRanks
Pulse Biosciences IDE Approval for Atrial Fibrillation Study - TradingView — Track All Markets
[8-K] PULSE BIOSCIENCES, INC. Reports Material Event | PLSE SEC FilingForm 8-K - Stock Titan
Pulse Biosciences Receives FDA Approval to Launch Cardiac Catheter Ablation Study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation - Investing News Network
FDA approves Pulse Biosciences’ atrial fibrillation trial - Investing.com
Pulse Biosciences announces FDA IDE approval to initiate its nPulse cardiac catheter ablation system study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study - TradingView — Track All Markets
Will Pulse Biosciences Inc. stock outperform tech sector in 2025Market Performance Recap & Scalable Portfolio Growth Ideas - Улправда
Pulse Biosciences Earnings Notes - Trefis
How (PLSE) Movements Inform Risk Allocation Models - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5%Here's What Happened - MarketBeat
Net current asset value per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Pulse Biosciences drops 38% after InvestingPro’s "Overvalued" warning By Investing.com - Investing.com Australia
Pulse Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Pulse Biosciences and MD Anderson to study nPulse for thyroid cancer - MSN
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor - sharewise.com
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
0.51%
1.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):